Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: A descriptive study

Expert Opinion on Drug Safety

Volumn 12, Issue 1, 2013, Pages 29-38

  Crijns, Ineke ^a,b   Mantel Teeuwisse, Aukje ^c   Bloemberg, Rudi ^a   Pinas, Eldridge ^b   Straus, Sabine ^b,d   De Jong Van Den Berg, Lolkje ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acne; Dermatology; Isotretinoin; Pregnancy; Prevention; Surveys

Indexed keywords

ISOTRETINOIN;

ADULT; AGED; CONTRACEPTION; DERMATOLOGIST; DESCRIPTIVE RESEARCH; FEMALE; HEALTH CARE PERSONNEL; HUMAN; INFORMATION DISSEMINATION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACIST; PREGNANCY TEST; PRESCRIPTION; RESPONSIBILITY; REVIEW;

ABNORMALITIES, DRUG-INDUCED; ATTITUDE OF HEALTH PERSONNEL; AWARENESS; COMMUNITY PHARMACY SERVICES; CONTRACEPTION; DERMATOLOGIC AGENTS; DERMATOLOGY; DRUG PRESCRIPTIONS; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PLAN IMPLEMENTATION; HUMANS; ISOTRETINOIN; NETHERLANDS; PATIENT EDUCATION AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY TESTS; PROGRAM EVALUATION; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS;

EID: 84871512091     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.745850     Document Type: Review

References (25)

1. Cheetham TC, Wagner RA, Chiu G, et al. A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort study. J Am Acad Dermatol 2006;55:442-8
2. Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 1992;26:599-606
3. Sladden MJ, Harman KE. What is the chance of a normal pregnancy in a women where fetus has been exposed to isotretinoin? Arch Dermatol 2007;143:1187-8
4. Lammer E, Chen D, Hoar R, et al. Retinoic acid embryopathy. NEJM 1985;313:837-41
5. Abroms L, Maibach E, Lyon-Daniel K, Feldman SR. What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med 2006;11:1978-83
6. Available from: http://www.ema.europa. eu/ema/index.jsp?curl=pages/ medicines/human/referrals/Isotretinoin/human-referral-000086. jsp&murl=menus/regulations/regulations. jsp&mid=WC0b01ac0580024e9a [Last accessed on 01 February 2012]
7. Crijns I, Straus S, Luteijn M, et al. Implementation of the harmonised EU isotretinoin Pregnancy Prevention Programme: a questionnaire survey among European regulatory agencies. Drug Saf 2012;35:27-32
8. Shin J, Cheetham T, Wong L, et al. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health system. J Am Acad Dermatol 2011;65:1117-25
9. Autret-Leca E, Kreft-Jais C, Elefant E, et al. Isotretinoin exposure during pregnancy -Assessment of spontaneous reports in France. Drug Saf 2010;33:659-65
10. ., ·Schaefer C, Meister RWeber-Schoendorfer C. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy. Arch Gynecol Obstet 2010;281:221-7
11. Teichert M, Visser L, Dufour M, et al. Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme A retrospective cohort study in females of reproductive age using pharmacy dispensing data. Drug Saf 2010;33:315-26
12. Crijns H, van Rein N, Gispen-de Wied C, et al. Prescriptive Contraceptive use among isotretinoin users in the Netherlands in comparison with nonusers: a drug utilisation study. Pharmacoepidemiol Drug Saf 2012;21(10):1060-6
13. Arriegas M, Pe'go A, Lemos M, Cle'rigo I. Isotretinoin -PPP compliance [abstract]. Drug Saf 2009;10:984
14. Jeanmougin M, Beaulieu P, Doutre M, Jaramillo C. Aide au bon usage de l'isotre'tinoi?n en pratique libe'rale: observatoire prospectif de 1263 patients acne'iques. Ann Dermatol Venereol 2009;136:54-61
15. Asbell PA, Spiegel S. Ophthalmologist perceptions regarding treatment of moderate to severe dry eye: results of a physician survey. Trans Am Ophthalmol Soc 2009;107:205-13
16. Handler SM, Shierts BH, Perera S, et al. Frequency of laboratory monitoring of chronic medications administered to nursing facility residents: results of a national Internet-based study. Consult Pharm 2008;23:387-95
17. Metcalfe PD, Elyas R. Foreskin management -Survey of Canadian pediatric urologists. Can Fam Physician 2010;56:e290-5
18. Wilbur K. Resident physician and hospital pharmacist familiarity with patient discharge medication costs. Pharm World Sci 2009;31:195-201
19. Van Gelder M, Bretveld R, Roeleveld N. Web-based questionnaires: the future in epidemiology? Am J Epidemiol 2010;172:1292-8
20. Boucher N, Beaulac-Baillargeon L. Pregnancy Prevention among women taking isotretinoin: failure to comply with the recommendations. Can Fam Physician 2006;52:339-42
21. Schwarz EB, Postlethwaite DA, Hung YY, Armstrong MA. Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-Age women. Ann Intern Med 2007;147:370-6
22. Be'rard A, Azoulay L, Koren G, et al. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007;63:196-205
23. Crijns H, Straus S, Gispen-de Wied C, de Jong-van den Berg L. Compliance with Pregnancy Prevention Programs of isotretinoin in Europe: a systematic review. Br J Dermatol 2011;164:238-44
24. Brinker A, Kornegay C, Nourjah P. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies. Arch Dermatol 2005;141:563-9
25. AlGhamdi K, Khurram H, Asiri Y, Mandil A. Dermatologists' level of compliance with the prescription guidelines of isotretinoin for females of childbearing potential. Int J Dermatol 2011;50:1094-8